InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) ...

Related Keywords

Germany ,United States ,Munich ,Bayern ,German ,Thomas Taapken ,Nielsc Riedemann ,Regina Lutz ,Laurie Doyle ,Katja Arnold ,Inflarx Stops Development Of Vilobelimab ,Inflarx Pharmaceuticals Inc ,Development Expenses ,European Union ,German Ministry Of Education ,Mc Services ,European Medicines Agency ,Nasdaq ,Development Of Vilobelimab ,Exchange Commission ,Drug Administration ,German Ministry Of Health ,Chief Executive Officer ,Positive Topline Results ,Single Ascending Dose ,Phasei Trial Support Best In Class Potential ,Pyoderma Gangrenosum ,Authorization Application ,Critically Ill ,European Committee ,Medicinal Products ,Human Use ,Emergency Use Authorization ,Cutaneous Squamous Cell Carcinoma ,German Ministry ,Chief Financial Officer ,Marketing Expenses ,Administrative Expenses ,Financial Result ,Cash Used ,Operating Activities ,Capital Resources ,Financial Information ,Annual Report ,Condensed Consolidated Statements ,Comprehensive Loss ,Comprehensive Income ,Financial Position ,Shareholder Equity ,Cash Flows ,Inflarx Pharmaceuticals ,Ann Arbor ,German Federal Government ,